Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Inclusion Criteria:

- Male and female patients 18 to 80 years (inclusive) of age.

- Patients are not treated for dyslipidemia with medications other than HMG-CoA
reductase inhibitors (statins) for at least 4 weeks prior to Day 1. Patients should
be on stable doses of current medications, if any, for at least 3 months to be
eligible.

- Patients must weigh at least 50 kg to participate in the study, and must have a body
mass index (BMI) within the range of 18 - 40 kg/m2.

Exclusion Criteria:

- Use of other investigational drugs at the time of enrollment

- History of hypersensitivity to any of the study drugs or to drugs of similar chemical
classes

- Use of lipid modifying agents (e.g. fenofibrate, niacin, omega-3 fatty acids, etc.)
other than statins will exclude subjects.

- Pregnant or nursing (lactating) women

- Diabetic patients whose plasma glucose is not well controlled by stable diabetic
treatment for at least 3 months

- Heavy smokers (smoke more than 10 cigarettes a day routinely and who cannot refrain
from smoking during the study).

- Women of child-bearing potential (WOCBP) can be included but must use highly
effective contraception

- Significant illness within two (2) weeks prior to initial dosing

- History of immunodeficiency diseases, including a positive HIV (ELISA and Western
blot) test result.

- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.